OBJECTIVE: To compare rates of preterm birth before 35 weeks based on cervical length measurement at 16-20 weeks in women with twin gestations who received17-α hydroxyprogesterone caproate (17OHPC) or placebo. METHODS: This is a secondary analysis of a randomised, double-blind, placebo-controlled trial of twin gestations exposed to 17OHPC or placebo. Baseline transvaginal ultrasound evaluation of cervical length was performed prior to treatment assignment at 16-20 weeks. Cervical length measurements were categorised according to the 10th, 25th, 50th and 75th percentiles in the women studied. The effect of 17OHPC administration in women with a short (25th percentile) and long (75th percentile) cervix was evaluated. RESULTS: Of 661 twin gestations studied, 221 (33.4%) women enrolled at 11 centers underwent cervical length measurement. The 10th, 25th, 50th, 75th percentiles for cervical length at 16-20 weeks were 32, 36, 40 and 44 mm, respectively. The risk of preterm birth <35 weeks was increased in women with a cervical length <25th percentile (55.8 vs. 36.9%, p=0.02). However, a cervical length >75th percentile at this gestational age interval was not protective for preterm birth (36.5 vs. 42.9%, p=0.42). Administration of 17OHPC did not reduce preterm birth before 35 weeks among those with either a short or a long cervix (64.3 vs. 45.8%, p=0.18 and 38.1 vs. 35.5%, p=0.85, respectively). CONCLUSION:Women with twin gestations and a cervical length below the 25th percentile at 16-20 weeks had higher rates of preterm birth. In this subgroup of women, 17 OHPC did not prevent preterm birth before 35 weeks gestation. A cervical length above the 75th percentile at 16-20 weeks did not significantly reduce the risk of preterm birth in this high risk population.
RCT Entities:
OBJECTIVE: To compare rates of preterm birth before 35 weeks based on cervical length measurement at 16-20 weeks in women with twin gestations who received 17-α hydroxyprogesterone caproate (17OHPC) or placebo. METHODS: This is a secondary analysis of a randomised, double-blind, placebo-controlled trial of twin gestations exposed to 17OHPC or placebo. Baseline transvaginal ultrasound evaluation of cervical length was performed prior to treatment assignment at 16-20 weeks. Cervical length measurements were categorised according to the 10th, 25th, 50th and 75th percentiles in the women studied. The effect of 17OHPC administration in women with a short (25th percentile) and long (75th percentile) cervix was evaluated. RESULTS: Of 661 twin gestations studied, 221 (33.4%) women enrolled at 11 centers underwent cervical length measurement. The 10th, 25th, 50th, 75th percentiles for cervical length at 16-20 weeks were 32, 36, 40 and 44 mm, respectively. The risk of preterm birth <35 weeks was increased in women with a cervical length <25th percentile (55.8 vs. 36.9%, p=0.02). However, a cervical length >75th percentile at this gestational age interval was not protective for preterm birth (36.5 vs. 42.9%, p=0.42). Administration of 17OHPC did not reduce preterm birth before 35 weeks among those with either a short or a long cervix (64.3 vs. 45.8%, p=0.18 and 38.1 vs. 35.5%, p=0.85, respectively). CONCLUSION:Women with twin gestations and a cervical length below the 25th percentile at 16-20 weeks had higher rates of preterm birth. In this subgroup of women, 17 OHPC did not prevent preterm birth before 35 weeks gestation. A cervical length above the 75th percentile at 16-20 weeks did not significantly reduce the risk of preterm birth in this high risk population.
Authors: E R Guzman; C Walters; C O'reilly-Green; W L Kinzler; R Waldron; J Nigam; A M Vintzileos Journal: Am J Obstet Gynecol Date: 2000-11 Impact factor: 8.661
Authors: Catherine Y Spong; Paul J Meis; Elizabeth A Thom; Baha Sibai; Mitchell P Dombrowski; Atef H Moawad; John C Hauth; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Menachem Miodovnik; Kenneth J Leveno; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe Journal: Am J Obstet Gynecol Date: 2005-09 Impact factor: 8.661
Authors: Dwight J Rouse; Steve N Caritis; Alan M Peaceman; Anthony Sciscione; Elizabeth A Thom; Catherine Y Spong; Michael Varner; Fergal Malone; Jay D Iams; Brian M Mercer; John Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper; Garland Anderson Journal: N Engl J Med Date: 2007-08-02 Impact factor: 91.245
Authors: Ashley S Roman; Andrei Rebarber; Leonardo Pereira; Anna K Sfakianaki; Jeanine Mulholland; Vincenzo Berghella Journal: J Ultrasound Med Date: 2005-06 Impact factor: 2.153
Authors: Roger B Newman; Jay D Iams; Anita Das; Robert L Goldenberg; Paul Meis; Atef Moawad; Baha M Sibai; Steve N Caritis; Menachem Miodovnik; Richard H Paul; Mitchell P Dombrowski; Molly Fischer Journal: Am J Obstet Gynecol Date: 2006-06-12 Impact factor: 8.661
Authors: Sophia M R Lannon; Jeroen P Vanderhoeven; David A Eschenbach; Michael G Gravett; Kristina M Adams Waldorf Journal: Reprod Sci Date: 2014-05-19 Impact factor: 3.060